Cardiogen vs Humanin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- ~4–8 hours (HNG)
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 2–8 mg
- Frequency
- Daily for 10–30 days
- 3–5 times per week
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Injection site irritation
- Limited human safety data available
- Stacks With
- —
- —